Literature DB >> 32152085

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.

Ernane Souza1, Ryan L Crass1, Jeremy Felton2, Kengo Hanaya3, Manjunath P Pai4.   

Abstract

In patients with renal impairment (n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  dialysis; myelosuppression; oxazolidinones; pharmacodynamics; toxicology

Mesh：

Substances：

Year:  2020        PMID： 32152085      PMCID： PMC7179609          DOI： 10.1128/AAC.00027-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Predicting myelosuppression of drugs from in silico models.

Authors:  Patrizia Crivori; Giulia Pennella; Miriam Magistrelli; Pietro Grossi; Anna Maria Giusti
Journal:  J Chem Inf Model       Date:  2011-01-28       Impact factor: 4.956

2.  Renal function as a predictor of linezolid-induced thrombocytopenia.

Authors:  Kazuaki Matsumoto; Yasuo Takeda; Ayumi Takeshita; Naoko Fukunaga; Akari Shigemi; Keiko Yaji; Yoshihiro Shimodozono; Katsushi Yamada; Kazuro Ikawa; Norifumi Morikawa
Journal:  Int J Antimicrob Agents       Date:  2008-09-14       Impact factor: 5.283

3.  Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports.

Authors:  Lea S Blaser; Alexandra Tramonti; Pascal Egger; Manuel Haschke; Stephan Krähenbühl; Alexandra E Rätz Bravo
Journal:  Eur J Clin Pharmacol       Date:  2014-11-18       Impact factor: 2.953

Review 4.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.

Authors:  Antonia F Stepan; Daniel P Walker; Jonathan Bauman; David A Price; Thomas A Baillie; Amit S Kalgutkar; Michael D Aleo
Journal:  Chem Res Toxicol       Date:  2011-07-11       Impact factor: 3.739

Review 5.  Linezolid: a promising option in the treatment of Gram-positives.

Authors:  Abed Zahedi Bialvaei; Mohammad Rahbar; Mehdi Yousefi; Mohammad Asgharzadeh; Hossein Samadi Kafil
Journal:  J Antimicrob Chemother       Date:  2016-12-20       Impact factor: 5.790

6.  Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity.

Authors:  Sonia Luque; Rosana Muñoz-Bermudez; Daniel Echeverría-Esnal; Luisa Sorli; Nuria Campillo; Javier Martínez-Casanova; Elena González-Colominas; Francisco Álvarez-Lerma; Juan Pablo Horcajada; Santiago Grau; Jason A Roberts
Journal:  Ther Drug Monit       Date:  2019-12       Impact factor: 3.681

7.  Measurement of Linezolid and Its Metabolites PNU-142300 and PNU-142586 in Human Plasma Using Ultra-Performance Liquid Chromatography Method.

Authors:  Norihiro Sakurai; Yasutaka Nakamura; Hiroshi Kawaguchi; Junko Abe; Koichi Yamada; Katsuya Nagayama; Hiroshi Kakeya
Journal:  Chem Pharm Bull (Tokyo)       Date:  2019       Impact factor: 1.645

Review 8.  Safety and tolerability of linezolid.

Authors:  Gary French
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

9.  Pharmacokinetics of linezolid in subjects with renal dysfunction.

Authors:  Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial.

Authors:  Dennis J Stalker; Gail L Jungbluth
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
View more
  6 in total

Review 1.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

2.  Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.

Authors:  Fan Wu; Xiao-Shan Zhang; Ying Dai; Zi-Ye Zhou; Chun-Hong Zhang; Lu Han; Fang-Min Xu; Ye-Xuan Wang; Da-Wei Shi; Guan-Yang Lin; Xu-Ben Yu; Fang Chen
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

3.  Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.

Authors:  Hitoshi Kawasuji; Yasuhiro Tsuji; Chika Ogami; Makito Kaneda; Yushi Murai; Kou Kimoto; Akitoshi Ueno; Yuki Miyajima; Yasutaka Fukui; Ippei Sakamaki; Yoshihiro Yamamoto
Journal:  Antibiotics (Basel)       Date:  2021-04-26

4.  Expert consensus statement on therapeutic drug monitoring and individualization of linezolid.

Authors:  Bin Lin; Yangmin Hu; Ping Xu; Tao Xu; Chunyan Chen; Le He; Mi Zhou; Zhangzhang Chen; Chunhong Zhang; Xuben Yu; Luo Fang; Junfeng Zhu; Yanlan Ji; Qun Lin; Hengbin Cao; Youqin Dai; Xiaoyan Lu; Changcheng Shi; Li Li; Changjiang Wang; Xumei Li; Qiongyan Fang; Jing Miao; Zhengyi Zhu; Guangyong Lin; Haichao Zhan; Shiwen Lv; Yalan Zhu; Xinjun Cai; Yin Ying; Meng Chen; Qiong Xu; Yiwen Zhang; Yubin Xu; Pea Federico; Saiping Jiang; Haibin Dai
Journal:  Front Public Health       Date:  2022-08-10

5.  A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency.

Authors:  Yingying Wang; Er-Min Gu; Xiaoxiang Du; Ren-Ai Xu; Guanyang Lin
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 6.  Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.

Authors:  Changcheng Shi; Junbo Xia; Jian Ye; Yaping Xie; Weizhong Jin; Wei Zhang; Liusheng Wang; Xuping Ding; Nengming Lin; Limin Wang
Journal:  Br J Clin Pharmacol       Date:  2021-10-10       Impact factor: 3.716
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.